ClinicalTrials.gg
CompletedNCT02096263Updated Nov 27, 2019Results posted

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

A Phase 3 interventional study of Infanrix hexa and Pediarix in Poliomyelitis, Diphtheria and Haemophilus Influenzae Type b, sponsored by GlaxoSmithKline. Completed at 43 sites in United States. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
585
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Poliomyelitis.

Enrollment
5th of 14
585 · median 467
Started
2014
the only one that year
Phase 3
7 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
13 of 14
GlaxoSmithKline

Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, this one is the 5th largest by enrollment, is the only one that started in 2014, is one of 7 in phase 3, and was the 12th registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

None of the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis is open now. The open studies under Poliomyelitis, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.

03

Conditions studied

  • Poliomyelitis
  • Diphtheria
  • Haemophilus Influenzae Type b
  • Tetanus
  • Acellular Pertussis
  • Hepatitis B

Keywords

  • Infants
  • Safety
  • Healthy
  • Infanrix Hexa
  • Immunogenicity
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects' parent(s)/ Legally Acceptable Representative(s) (LARs) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
  • A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
  • Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed weeks [259 to 293 days]).
  • Written obtained from parent(s)/LAR(s) of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Infants who have not received a previous dose of vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.

Exclusion criteria

Exclusion Criteria:

  • Child in care
  • Use of any or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period.
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs since birth. For , this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting from 30 days before the first vaccination until 30 days after Dose 3 (Epoch 001, primary vaccination) and from 30 days before the booster Dose 4 until 30 days after booster Dose 4 (Epoch 002, booster vaccination), i.e. the end of the study:

    • Inactivated influenza and hepatitis A vaccines are allowed throughout the study.
    • Routine administration(s) of vaccines are allowed from 30 days after the last dose of primary vaccination until 30 days before the booster dose and after post-booster blood sampling. Routine administration of measles-mumps-rubella vaccine, varicella, pneumococcal vaccines are allowed from 30 days after last dose of primary vaccine until 30 days before booster dose and from post-booster blood sampling, as well as according to the recommended immunization schedule in US.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and diseases.
  • Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or likely to be exacerbated by any component of the vaccines (including yeast).
  • Hypersensitivity to latex.
  • Major congenital defects or serious chronic illness.
  • History of any neurological disorders including seizures.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • History of intussusception or of any uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.
  • History of Severe Combined Immunodeficiency Disease (SCID).
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.
    • Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
585 participants (actual)

Study arms

  • Experimental
    Infanrix hexa Group

    Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.

    Biological: Infanrix hexa · Biological: Infanrix · Biological: Hiberix · Biological: Prevnar13 · Biological: Rotarix

  • Active comparator
    Pediarix Group

    Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.

    Biological: Pediarix · Biological: ActHIB · Biological: Infanrix · Biological: Prevnar13 · Biological: Rotarix

  • Active comparator
    Pentacel Group

    Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.

    Biological: Pentacel · Biological: Engerix-B · Biological: Prevnar13 · Biological: Rotarix

Interventions

06

What researchers measure

Primary outcomes

  1. Antibody Concentrations for Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN).

    Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN. The results for the Infanrix hexa Group and Pediarix Group were the primary outcome variables.

    Time frame: At Month 5, one month after the third dose of the primary vaccination.

Secondary outcomes

  1. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.

    A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

    Time frame: At Month 5, one month after the third dose of the primary vaccination.

  2. Number of Seroprotected Subjects Against Tetanus (T).

    A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination.

  3. Number of Seroprotected Subjects Against Diphtheria (D).

    A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination.

  4. Antibody Concentrations for Anti-T.

    Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  5. Antibody Concentrations for Anti-D.

    Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  6. Number of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.

    A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  7. Antibody Titres for Anti-polio Types 1, 2 and 3.

    Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  8. Number of Seroprotected Subjects Against Polyribosyl Ribitol Phosphate (Anti-PRP).

    A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  9. Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.

    The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  10. Antibody Concentrations for Anti-PRP.

    Antibody concentrations were expressed as GMCs for the assay cut-off of 1 µg/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  11. Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs).

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mili-International units per mililiter (mIU/mL).

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  12. Antibody Concentrations for Anti-HBs.

    Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.

    Time frame: At Month 5, one month after the third dose of the primary vaccination

  13. Number of Subjects With Solicited Local Symptoms.

    The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 1

  14. Number of Subjects With Solicited Local Symptoms.

    The solicited local symptoms assessed were pain, redness (Red) and swelling (Swe). Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 2

  15. Number of Subjects With Solicited Local Symptoms.

    The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness (Red)/Swelling (Swe): \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA

    Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 3

  16. Number of Subjects With Solicited Local Symptoms.

    The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following any dose.

  17. Number of Subjects With Solicited General Symptoms.

    The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 1.

  18. Number of Subjects With Solicited General Symptoms.

    The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 2.

  19. Number of Subjects With Solicited General Symptoms.

    The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Feve:r \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following Dose 3.

  20. Number of Subjects With Solicited General Symptoms.

    The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following any dose.

  21. Number of Subjects With Specific Adverse Events (AEs).

    Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)

    Time frame: From Month 0 up to 6 months post primary-vaccination (Month 10)

  22. Number of Subjects With Unsolicited AEs.

    An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: During the 31-day (Days 0-30) post-primary vaccination period.

  23. Number of Subjects With Serious Adverse Events (SAEs).

    SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

    Time frame: From Month 0 up to 6 months post-primary vaccination (Month 10)

  24. Number of Seroprotected Subjects Against Anti-T.

    A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 (At Month 14-17 one month after the booster dose (Dose 4)]

  25. Number of Seroprotected Subjects Against Anti-D.

    A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 (At Month 14-17 one month after the booster dose (Dose 4)]

  26. Antibody Concentrations for Anti-T.

    Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]

  27. Antibody Concentrations for Anti-D.

    Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]

  28. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.

    A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

    Time frame: At Visit 5 [Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [Month 14-17 one month after the booster dose (Dose 4)]

  29. Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN.

    Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

    Time frame: At Visit 5 [Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [Month 14-17 one month after the booster dose (Dose 4)]

  30. Number of Subjects With a Booster Response for Anti-PT, Anti-FHA and Anti-PRN.

    Booster response to PT, FHA and PRN antigens was defined as: * For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration equal or above 4 times the assay cut-off. * For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cut-off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration. * For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut-off, post-vaccination antibody concentration of at least two times the pre-vaccination antibody concentration. The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

    Time frame: At Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]

  31. Number of Seroprotected Subjects Against Anti-PRP.

    A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose4)]

  32. Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.

    The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose4)]

  33. Antibody Concentrations for Anti-PRP.

    Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 1 µg/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]

  34. Number of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.

    A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]

  35. Antibody Titres for Anti-polio Types 1, 2 and 3.

    Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]

  36. Number of Seroprotected Subjects Against Anti-HBs.

    A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]

  37. Antibody Concentrations for Anti-HBs.

    Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.

    Time frame: At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]

  38. Number of Subjects With Solicited Local Symptoms.

    The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

    Time frame: During the 4-day (Days 0-3) post-booster vaccination.

  39. Number of Subjects With Solicited General Symptoms.

    The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C and ≤ 40.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

    Time frame: During the 4-day (Days 0-3) post-booster vaccination.

  40. Number of Subjects With Specific AEs.

    Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)

    Time frame: During the 31-day (Days 0-30) post-booster vaccination.

  41. Number of Subjects With Unsolicited AEs.

    An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

    Time frame: During the 31-day (Days 0-30) post-booster vaccination.

  42. Number of Subjects With SAEs.

    SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

    Time frame: During the 31-day (Days 0-30) post-booster vaccination.

07

Results

Posted Aug 1, 2018

Participant flow

This study was conducted in 43 centers in the United States of America (USA).

Participant flow — Overall Study
MilestoneInfanrix Hexa GroupPediarix GroupPentacel Group
Started195194196
Completed161158157
Not completed343639
Withdrew: Adverse event101
Withdrew: Lost to follow-up141815
Withdrew: Other796
Withdrew: Sponsor study termination001
Withdrew: Protocol violation728
Withdrew: Withdrawal by subject578

Outcome measures

PrimaryAntibody Concentrations for Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN).

Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN. The results for the Infanrix hexa Group and Pediarix Group were the primary outcome variables.

Time frame:
At Month 5, one month after the third dose of the primary vaccination.
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN).
IU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PT43.2 (38.1 to 48.9)48.3 (42.7 to 54.5)24.2 (21.1 to 27.7)
Anti-FHA106.3 (95.0 to 119.0)122.7 (109.9 to 137.0)59.9 (51.7 to 69.3)
Anti-PRN57.4 (49.5 to 66.6)46.9 (39.9 to 55.3)33.0 (27.8 to 39.1)
Statistical analysis
  • Infanrix Hexa Group vs Pediarix Group · Adjusted gmc ratio: 1.1 · 95% CI 0.92 to 1.31Adjusted GMC (ANCOVA model adjusted with the vaccine group as fixed effect and the Infanrix vaccination history of the mother during pregnancy as continuous regressor).
  • Infanrix Hexa Group vs Pediarix Group · Adjusted gmc ratio: 1.14 · 95% CI 0.97 to 1.35Adjusted GMC (ANCOVA model adjusted with the vaccine group as fixed effect and the Infanrix vaccination history of the mother during pregnancy as continuous regressor).
  • Infanrix Hexa Group vs Pediarix Group · Adjusted gmc ratio: 0.79 · 95% CI 0.63 to 0.99Adjusted GMC (ANCOVA model adjusted with the vaccine group as fixed effect and the Tdap vaccination history of the mother during pregnancy as continuous regressor.).
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.

A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Time frame:
At Month 5, one month after the third dose of the primary vaccination.
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PT146148148
Anti-FHA146149149
Anti-PRN146148148
SecondaryNumber of Seroprotected Subjects Against Tetanus (T).

A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination.
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Tetanus (T).
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Seroprotected Subjects Against Tetanus (T).146149148
SecondaryNumber of Seroprotected Subjects Against Diphtheria (D).

A seroprotected subject was defined a a subject with antibody concentrations ≥ 0.1 IU/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination.
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria (D).
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Seroprotected Subjects Against Diphtheria (D).142144149
SecondaryAntibody Concentrations for Anti-T.

Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Anti-T.
IU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Antibody Concentrations for Anti-T.2.458 (2.195 to 2.753)2.633 (2.338 to 2.966)2.012 (1.768 to 2.290)
SecondaryAntibody Concentrations for Anti-D.

Concentrations were expressed as GMCs for the seroprotection cut-off of 0.1 IU/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Anti-D.
IU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Antibody Concentrations for Anti-D.1.777 (1.551 to 2.036)1.648 (1.44 to 1.886)1.249 (1.095 to 1.425)
SecondaryNumber of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.

A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-polio 1137134135
Anti-polio 2133131134
Anti-polio 3129132124
SecondaryAntibody Titres for Anti-polio Types 1, 2 and 3.

Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Geometric mean · titres
Antibody Titres for Anti-polio Types 1, 2 and 3.
titresInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-polio 1546.9 (447.7 to 668.0)604.1 (495.9 to 736.0)319.5 (256.8 to 397.5)
Anti-polio 2483.5 (394.2 to 593.0)567.7 (448.8 to 718.1)283.0 (229.4 to 349.2)
Anti-polio 3722.2 (577.4 to 903.4)927.0 (740.7 to 1160.3)294.6 (221.6 to 391.7)
SecondaryNumber of Seroprotected Subjects Against Polyribosyl Ribitol Phosphate (Anti-PRP).

A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Polyribosyl Ribitol Phosphate (Anti-PRP).
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Seroprotected Subjects Against Polyribosyl Ribitol Phosphate (Anti-PRP).146151154
SecondaryNumber of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.

The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.85145130
SecondaryAntibody Concentrations for Anti-PRP.

Antibody concentrations were expressed as GMCs for the assay cut-off of 1 µg/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Geometric mean · µg/mL
Antibody Concentrations for Anti-PRP.
µg/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Antibody Concentrations for Anti-PRP.1.348 (1.076 to 1.688)9.258 (7.362 to 11.642)5.717 (4.363 to 7.492)
SecondaryNumber of Seroprotected Subjects Against Hepatitis B (Anti-HBs).

A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mili-International units per mililiter (mIU/mL).

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs).
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs).134138133
SecondaryAntibody Concentrations for Anti-HBs.

Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.

Time frame:
At Month 5, one month after the third dose of the primary vaccination
Reported as:
Geometric mean · mIU/mL
Antibody Concentrations for Anti-HBs.
mIU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Antibody Concentrations for Anti-HBs.2258.8 (1910.7 to 2670.4)1886.0 (1565.6 to 2271.9)1053.4 (780.2 to 1422.4)
SecondaryNumber of Subjects With Solicited Local Symptoms.

The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following Dose 1
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Pain, ActHIB/EngerixNA123100
≥ G 2 Pain, ActHIB/EngerixNA6645
G 3 Pain, ActHIB/EngerixNA2210
MA Pain, ActHIB/EngerixNA10
Any Pain, Infanrix hexa/Pediarix/Pentacel94113115
≥ G 2 Pain, Infanrix hexa/Pediarix/Pentacel406551
G 3 Pain, Infanrix hexa/Pediarix/Pentacel81712
MA Pain, Infanrix hexa/Pediarix/Pentacel100
Any Redness, ActHIB/EngerixNA6355
≥ G 2 Redness, ActHIB/EngerixNA1912
G 3 Redness, ActHIB/EngerixNA81
MA Redness, ActHIB/EngerixNA10
Any Redness, Infanrix hexa/Pediarix/Pentacel475657
≥ G 2 Redness, Infanrix hexa/Pediarix/Pentacel151520
G 3 Redness, Infanrix hexa/Pediarix/Pentacel343
MA Redness, Infanrix hexa/Pediarix/Pentacel000
Any Swelling, ActHIB/EngerixNA4139
≥ G 2 Swelling, ActHIB/EngerixNA1414
G 3 Swelling, ActHIB/EngerixNA63
MA Swelling, ActHIB/EngerixNA10
Any Swelling, Infanrix hexa/Pediarix/Pentacel313545
≥ G 2 Swelling, Infanrix hexa/Pediarix/Pentacel101424
G 3 Swelling, Infanrix hexa/Pediarix/Pentacel2311
MA Swelling, Infanrix hexa/Pediarix/Pentacel000
SecondaryNumber of Subjects With Solicited Local Symptoms.

The solicited local symptoms assessed were pain, redness (Red) and swelling (Swe). Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following Dose 2
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Pain, ActHIB/EngerixNA1046
≥ G 2 Pain, ActHIB/EngerixNA472
G 3 Pain, ActHIB/EngerixNA90
MA Pain, ActHIB/EngerixNA00
Any Pain,Infanrix/Pediarix/Pentacel8410893
≥G2 Pain,Infanrix/Pediarix/Pentacel254431
G3 Pain,Infanrix/Pediarix/Pentacel176
MA Pain, Infanrix/Pediarix/Pentacel000
Any Redness, ActHIB/EngerixNA665
≥ G 2 Redness, ActHIB/EngerixNA171
G 3 Redness, ActHIB/EngerixNA10
MA Redness, ActHIB/EngerixNA00
Any Red, Infanrix/Pediarix/Pentacel596164
≥G2 Red,Infanrix/Pediarix/Pentacel151215
G 3 Red, Infanrix/Pediarix/Pentacel332
MA Red, Infanrix/Pediarix/Pentacel000
Any Swelling, ActHIB/EngerixNA403
≥ G 2 Swelling, ActHIB/EngerixNA110
G 3 Swelling, ActHIB/EngerixNA10
MA Swelling, ActHIB/EngerixNA00
Any Swe, Infanrix/Pediarix/Pentacel414042
≥G2 Swe, Infanrix/Pediarix/Pentacel10127
G 3 Swe, Infanrix/Pediarix/Pentacel223
MA Swe, Infanrix/Pediarix/Pentacel000
SecondaryNumber of Subjects With Solicited Local Symptoms.

The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness/Swelling: \> 5 millimeters (mm); Grade 3 Redness (Red)/Swelling (Swe): \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA

Time frame:
During the 4-day (Days 0-3) post-vaccination period following Dose 3
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Pain, ActHIB/EngerixNA9375
≥ G 2 Pain, ActHIB/EngerixNA4125
G 3 Pain, ActHIB/EngerixNA75
MA Pain, ActHIB/EngerixNA10
Any Pain, Infanrix/Pediarix/Pentacel679076
≥ G2 Pain, Infanrix/Pediarix/Pentacel183920
G3 Pain, Infanrix/Pediarix/Pentacel077
MA Pain, Infanrix/Pediarix/Pentacel010
Any Red, ActHIB/EngerixNA6951
≥ G 2 Red, ActHIB/EngerixNA79
G 3 Red, ActHIB/EngerixNA12
MA Red, ActHIB/EngerixNA00
Any Red, Infanrix/Pediarix/Pentacel636656
≥G2 Red, Infanrix/Pediarix/Pentacel71211
G3 Red, Infanrix/Pediarix/Pentacel130
MA Red, Infanrix/Pediarix/Pentacel010
Any Swe, ActHIB/EngerixNA4237
≥ G 2 Swe, ActHIB/EngerixNA77
G 3 Swe, ActHIB/EngerixNA10
MA Swe, ActHIB/EngerixNA00
Any Swe, Infanrix/Pediarix/Pentacel434435
≥ G2 Swe, Infanrix/Pediarix/Pentacel7104
G3 Swe, Infanrix/Pediarix/Pentacel130
MA Swe, Infanrix/Pediarix/Pentacel010
SecondaryNumber of Subjects With Solicited Local Symptoms.

The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following any dose.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Pain, ActHIB/EngerixNA148127
≥ G 2 Pain, ActHIB/EngerixNA9662
G 3 Pain, ActHIB/EngerixNA3014
MA Pain, ActHIB/EngerixNA20
Any Pain, Infanrix/Pediarix/Pentacel127151147
≥ G2 Pain, Infanrix/Pediarix/Pentacel589380
G3 Pain, Infanrix/Pediarix/Pentacel82722
MA Pain, Infanrix/Pediarix/Pentacel110
Any Red, ActHIB/EngerixNA10877
≥ G 2 Red, ActHIB/EngerixNA3820
G 3 Red, ActHIB/EngerixNA103
MA Red, ActHIB/EngerixNA10
Any Red, Infanrix/Pediarix/Pentacel949887
≥ G2 Red, Infanrix/Pediarix/Pentacel273237
G3 Red, Infanrix/Pediarix/Pentacel795
MA Red, Infanrix/Pediarix/Pentacel010
Any Swe, ActHIB/EngerixNA7864
≥ G 2 Swe, ActHIB/EngerixNA2518
G 3 Swe, ActHIB/EngerixNA73
MA Swe, ActHIB/EngerixNA10
Any Swe, Infanrix/Pediarix/Pentacel737072
≥ G2 Swe, Infanrix/Pediarix/Pentacel202626
G3 Swe, Infanrix/Pediarix/Pentacel4712
MA Swe, Infanrix/Pediarix/Pentacel010
SecondaryNumber of Subjects With Solicited General Symptoms.

The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following Dose 1.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Drowsiness114143149
≥ G 2 Drowsiness365653
G 3 Drowsiness3812
Rel Drowsiness112136141
G3 Rel Drowsiness3712
MA Drowsiness100
Any Irritability / Fussiness115165153
≥ G 2 Irritability / Fussiness427968
G 3 Irritability / Fussiness91715
Rel Irritability / Fussiness113163147
G3 Rel Irritability / Fussiness91715
MA Irritability / Fussiness100
Any Loss of appetite537680
≥ G 2 Loss of appetite81326
G 3 Loss of appetite014
Rel Loss of appetite487377
G3 Rel Loss of appetite014
MA Loss of appetite000
Any Fever223429
≥ G 2 Fever002
G 3 Fever000
Rel Fever153127
G3 Rel Fever000
MA Fever000
SecondaryNumber of Subjects With Solicited General Symptoms.

The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following Dose 2.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Drowsiness97132109
≥ G 2 Drowsiness314339
G 3 Drowsiness874
Rel Drowsiness94126108
G3 Rel Drowsiness773
MA Drowsiness000
Any Irritability / Fussiness128147136
≥ G 2 Irritability / Fussiness537061
G 3 Irritability / Fussiness61411
Rel Irritability / Fussiness125143133
G3 Rel Irritability / Fussiness61311
MA Irritability / Fussiness002
Any Loss of appetite565556
≥ G 2 Loss of appetite171515
G 3 Loss of appetite112
Rel Loss of appetite525155
G3 Rel Loss of appetite112
MA Loss of appetite001
Any Fever473635
≥ G 2 Fever232
G 3 Fever000
Rel Fever373233
G3 Rel Fever000
MA Fever000
SecondaryNumber of Subjects With Solicited General Symptoms.

The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Feve:r \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following Dose 3.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Drowsiness8510888
≥ G 2 Drowsiness233725
G 3 Drowsiness359
Rel Drowsiness8110586
G3 Rel Drowsiness359
MA Drowsiness021
Any Irritability / Fussiness126135122
≥ G 2 Irritability / Fussiness465858
G 3 Irritability / Fussiness61511
Rel Irritability / Fussiness121129120
G3 Rel Irritability / Fussiness61311
MA Irritability / Fussiness031
Any Loss of appetite455853
≥ G 2 Loss of appetite111315
G 3 Loss of appetite122
Rel Loss of appetite445652
G3 Rel Loss of appetite122
MA Loss of appetite010
Any Fever404537
≥ G 2 Fever4117
G 3 Fever020
Rel Fever353935
G3 Rel Fever020
MA Fever121
SecondaryNumber of Subjects With Solicited General Symptoms.

The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following any dose.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Drowsiness147172168
≥ G 2 Drowsiness678881
G 3 Drowsiness111922
Rel Drowsiness144169166
G3 Rel Drowsiness111821
MA Drowsiness121
Any Irritability / Fussiness164182177
≥ G 2 Irritability / Fussiness96128120
G 3 Irritability / Fussiness183530
Rel Irritability / Fussiness161180175
G3 Rel Irritability / Fussiness183430
MA Irritability / Fussiness133
Any Loss of appetite95111117
≥ G 2 Loss of appetite283239
G 3 Loss of appetite236
Rel Loss of appetite91108116
G3 Rel Loss of appetite236
MA Loss of appetite011
Any Fever727872
≥ G 2 Fever61410
G 3 Fever020
Rel Fever617469
G3 Rel Fever020
MA Fever121
SecondaryNumber of Subjects With Specific Adverse Events (AEs).

Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)

Time frame:
From Month 0 up to 6 months post primary-vaccination (Month 10)
Reported as:
Count of participants · Participants
Number of Subjects With Specific Adverse Events (AEs).
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With Specific Adverse Events (AEs).71110
SecondaryNumber of Subjects With Unsolicited AEs.

An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
During the 31-day (Days 0-30) post-primary vaccination period.
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited AEs.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With Unsolicited AEs.11310896
SecondaryNumber of Subjects With Serious Adverse Events (SAEs).

SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

Time frame:
From Month 0 up to 6 months post-primary vaccination (Month 10)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs).
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With Serious Adverse Events (SAEs).717
SecondaryNumber of Seroprotected Subjects Against Anti-T.

A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 (At Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-T.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-T at Visit 5118123107
Anti-T at Visit 6138136125
SecondaryNumber of Seroprotected Subjects Against Anti-D.

A seroprotected subject was defined a subject with antibody concentrations ≥ 0.1 IU/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 (At Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-D.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-D at Visit 5128123115
Anti-D at Visit 6138136126
SecondaryAntibody Concentrations for Anti-T.

Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Anti-T.
IU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-T at Visit 50.327 (0.281 to 0.380)0.402 (0.340 to 0.474)0.340 (0.281 to 0.410)
Anti-T at Visit 69.212 (7.863 to 10.793)8.870 (7.668 to 10.261)6.880 (5.905 to 8.015)
SecondaryAntibody Concentrations for Anti-D.

Concentrations were expressed as GMCs for the seropositivity cut-off of 0.1 IU/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Anti-D.
IU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-D at Visit 50.701 (0.597 to 0.825)0.622 (0.514 to 0.753)0.764 (0.629 to 0.928)
Anti-D at Visit 68.334 (7.479 to 9.286)7.886 (6.972 to 8.92)8.537 (7.524 to 9.687)
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.

A seropositive subject was defined as a subject with antibody concentrations above to or equal to (≥) 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Time frame:
At Visit 5 [Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PT at Visit 510711463
Anti-FHA at Visit 5130130113
Anti-PRN at Visit 511010491
Anti-PT at Visit 6138136126
Anti-FHA at Visit 6138136126
Anti-PRN at Visit 6136136124
SecondaryAntibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN.

Concentrations were expressed as geometric mean concentrations (GMCs) for the following cut-offs:2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Time frame:
At Visit 5 [Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Geometric mean · IU/mL
Antibody Concentrations for Anti-PT, Anti-FHA and Anti-PRN.
IU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PT Visit 55.3 (4.6 to 6.2)6.5 (5.6 to 7.7)3.1 (2.6 to 3.7)
Anti-FHA Visit 517.1 (14.7 to 19.9)21.8 (18.3 to 26.1)8.1 (6.6 to 9.9)
Anti-PRN Visit 56.8 (5.5 to 8.3)5.5 (4.5 to 6.6)6.0 (4.8 to 7.5)
Anti-PT Visit 671.4 (62.6 to 81.5)87.6 (76.6 to 100.2)55.5 (47.4 to 65.1)
Anti-FHA Visit 6186.9 (165.1 to 211.5)250.4 (220.4 to 284.6)101.0 (86.2 to 118.3)
Anti-PRN Visit 6208.0 (172.3 to 251.1)215.6 (176.1 to 263.8)130.5 (105.9 to 160.9)
SecondaryNumber of Subjects With a Booster Response for Anti-PT, Anti-FHA and Anti-PRN.

Booster response to PT, FHA and PRN antigens was defined as: * For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration equal or above 4 times the assay cut-off. * For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cut-off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration. * For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut-off, post-vaccination antibody concentration of at least two times the pre-vaccination antibody concentration. The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Time frame:
At Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Count of participants · Participants
Number of Subjects With a Booster Response for Anti-PT, Anti-FHA and Anti-PRN.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PT126121111
Anti-FHA130127114
Anti-PRN128128112
SecondaryNumber of Seroprotected Subjects Against Anti-PRP.

A seroprotected subject was defined as a subject with anti-PRP concentrations ≥ 0.15 µg/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose4)]
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-PRP.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PRP at Visit 59112294
Anti-PRP at Visit 6138139129
SecondaryNumber of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.

The cut-off for this assay was an anti-PRP concentration ≥ 1 µg/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose4)]
Reported as:
Count of participants · Participants
Number of Subjects With Anti-PRP Antibody Concentrations ≥ 1 µg/mL.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PRP at Visit 5237147
Anti-PRP at Visit 6136138128
SecondaryAntibody Concentrations for Anti-PRP.

Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 1 µg/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)] and at Visit 6 [At Month 14-17 one month after the booster dose (Dose 4)]
Reported as:
Geometric mean · µg/mL
Antibody Concentrations for Anti-PRP.
µg/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-PRP at Visit 50.301 (0.242 to 0.373)0.987 (0.775 to 1.256)0.614 (0.458 to 0.822)
Anti-PRP at Visit 639.365 (31.520 to 49.164)51.140 (41.954 to 62.339)27.318 (21.140 to 35.302)
SecondaryNumber of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.

A seroprotected subject was defined as a subject with anti-polio types 1, 2 and 3 titres ≥ 8 dilution.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-polio Types 1, 2 and 3.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-polio 1124121100
Anti-polio 2119122109
Anti-polio 312312680
SecondaryAntibody Titres for Anti-polio Types 1, 2 and 3.

Titres were expressed as geometric mean titres (GMTs) for the cut-off of 8 dilution.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Reported as:
Geometric mean · titres
Antibody Titres for Anti-polio Types 1, 2 and 3.
titresInfanrix Hexa GroupPediarix GroupPentacel Group
Anti-polio 199.5 (79.4 to 124.8)107.4 (83.7 to 137.9)42.2 (32.6 to 54.6)
Anti-polio 294.9 (73.2 to 123.1)111.9 (88.0 to 142.4)51.2 (40.8 to 64.3)
Anti-polio 3122.1 (95.1 to 156.9)160.4 (125.8 to 204.6)28.4 (20.6 to 39.1)
SecondaryNumber of Seroprotected Subjects Against Anti-HBs.

A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-HBs.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Seroprotected Subjects Against Anti-HBs.131128105
SecondaryAntibody Concentrations for Anti-HBs.

Antibody concentrations were expressed as GMCs for the seroprotection cut-off of 10 mIU/mL.

Time frame:
At Visit 5 [At Month 13-16 before the booster dose (Dose 4)]
Reported as:
Geometric mean · mIU/mL
Antibody Concentrations for Anti-HBs.
mIU/mLInfanrix Hexa GroupPediarix GroupPentacel Group
Antibody Concentrations for Anti-HBs.328.7 (261.5 to 413.2)235.8 (188.2 to 295.5)149.4 (100.5 to 222.3)
SecondaryNumber of Subjects With Solicited Local Symptoms.

The solicited local symptoms assessed were pain, redness and swelling. Any = any reports of the specific symptom irrespective of intensity grade; above or equal (≥); Grade 2 Redness (Red)/Swelling (Swe): \> 5 millimeters (mm); Grade 3 Redness/Swelling: \> 20 mm; Grade 2 Pain = Moderate: cries/protests on touch; Grade 3 Pain = Severe: Cries when limb is moved/spontaneously painful. Grade = G; Medical Advice = MA.

Time frame:
During the 4-day (Days 0-3) post-booster vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Pain, ActHIB/Hiberix6164NA
≥ G 2 Pain, ActHIB/Hiberix1115NA
G 3 Pain, ActHIB/Hiberix12NA
MA Pain, ActHIB/Hiberix00NA
Any Pain, Infanrix/Pentacel627459
≥ G2 Pain, Infanrix/Pentacel121916
G3 Pain, Infanrix/Pentacel232
MA Pain, Infanrix/Pentacel100
Any Red, ActHIB/Hiberix4249NA
≥ G 2 Red, ActHIB/Hiberix74NA
G 3 Red, ActHIB/Hiberix02NA
MA Red, ActHIB/Hiberix00NA
Any Red, Infanrix/Pentacel496047
≥ G2 Red, Infanrix/Pentacel171413
G3 Red, Infanrix/Pentacel842
MA Red, Infanrix/Pentacel200
Any Swe, ActHIB/Hiberix2929NA
≥ G 2 Swe, ActHIB/Hiberix76NA
G 3 Swe, ActHIB/Hiberix02NA
MA Swe, ActHIB/Hiberix00NA
Any Swe, Infanrix/Pentacel424435
≥ G2 Swe, Infanrix/Pentacel131714
G3 Swe, Infanrix/Pentacel574
MA Swe, Infanrix/Pentacel200
SecondaryNumber of Subjects With Solicited General Symptoms.

The solicited general symptoms assessed were Drowsiness, Irritability/Fussiness, Loss Of Appetite and Fever (defined as temperature ≥ 38.0°C). Any = any reports of the specific symptom irrespective of intensity grade; Grade 2 (G2) Drowsiness = Drowsiness that interfered with normal activity; Grade 2 Irritability/Fussiness = Moderate: Cried more than usual/interfered with normal activity; Grade 2 Loss of appetite = Ate less than usual/interfered with normal activity; Grade 2 Fever: \> 39.0 °C and ≤ 40.0 °C; Grade 3 (G3) Drowsiness/Irritability/Fussiness = symptom that prevented normal activity; Grade 3 Loss of appetite = Did not eat at all; Grade 3 Fever: \> 40.0 °C; Related (Rel) = Symptom which was assessed by the investigator as related to vaccination.

Time frame:
During the 4-day (Days 0-3) post-booster vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Any Drowsiness596765
≥ G 2 Drowsiness182017
G 3 Drowsiness132
Rel Drowsiness556561
G3 Rel Drowsiness132
MA Drowsiness000
Any Irritability / Fussiness869476
≥ G 2 Irritability / Fussiness263523
G 3 Irritability / Fussiness344
Rel Irritability / Fussiness859268
G3 Rel Irritability / Fussiness344
MA Irritability / Fussiness001
Any Loss of appetite474746
≥ G 2 Loss of appetite8911
G 3 Loss of appetite122
Rel Loss of appetite444441
G3 Rel Loss of appetite122
MA Loss of appetite000
Any Fever41011
≥ G 2 Fever111
G 3 Fever000
Rel Fever2109
G3 Rel Fever000
MA Fever021
SecondaryNumber of Subjects With Specific AEs.

Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies)

Time frame:
During the 31-day (Days 0-30) post-booster vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Specific AEs.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With Specific AEs.411
SecondaryNumber of Subjects With Unsolicited AEs.

An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Time frame:
During the 31-day (Days 0-30) post-booster vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited AEs.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With Unsolicited AEs.373541
SecondaryNumber of Subjects With SAEs.

SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.

Time frame:
During the 31-day (Days 0-30) post-booster vaccination.
Reported as:
Count of participants · Participants
Number of Subjects With SAEs.
ParticipantsInfanrix Hexa GroupPediarix GroupPentacel Group
Number of Subjects With SAEs.101

Adverse events

Collected over Solicited local and general symptoms: during the 4-day (Day 0-Day 3) follow-up period after each dose. Unsolicited AEs: during the 31-day (Day 0-Day 30) follow-up period after each dose. SAEs: during the entire study period (from Month 0 to Month 17).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infanrix Hexa Group0/195 (0%)8/195 (4.1%)188/195 (96.4%)
Pediarix Group0/194 (0%)1/194 (0.5%)190/194 (97.9%)
Pentacel Group0/196 (0%)8/196 (4.1%)187/196 (95.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventInfanrix Hexa GroupPediarix GroupPentacel Group
Respiratory distressRespiratory, thoracic and mediastinal disorders3/1950/1940/196
Parainfluenzae virus infectionInfections and infestations0/1950/1942/196
Gastroenteritis viralInfections and infestations1/1951/1940/196
LeukocytosisBlood and lymphatic system disorders1/1950/1940/196
Gastrooesophageal reflux diseaseGastrointestinal disorders1/1950/1940/196
Meningitis viralInfections and infestations1/1950/1940/196
Respiratory syncytial virus bronchiolitisInfections and infestations1/1950/1941/196
Near drowningInjury, poisoning and procedural complications1/1950/1940/196
DehydrationMetabolism and nutrition disorders1/1950/1941/196
HyponatraemiaMetabolism and nutrition disorders1/1950/1940/196
Most frequent other events
Showing 10 of 174
Most frequent other events
EventInfanrix Hexa GroupPediarix GroupPentacel Group
IrritabilityPsychiatric disorders167/195183/194180/196
SomnolenceNervous system disorders152/195173/194173/196
Injection site painGeneral disorders141/195162/194152/196
Injection site erythemaGeneral disorders112/195129/194116/196
Decreased appetiteMetabolism and nutrition disorders112/195126/194127/196
Injection site swellingGeneral disorders92/195103/19490/196
PyrexiaGeneral disorders82/19585/19482/196
Upper respiratory tract infectionInfections and infestations32/19526/19432/196
CoughRespiratory, thoracic and mediastinal disorders17/1958/1947/196
VomitingGastrointestinal disorders13/19510/19412/196

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Infanrix Hexa GroupPediarix GroupPentacel GroupTotal
Mean8.5 ± 1.08.6 ± 1.18.6 ± 1.18.6 ± 1.1
Sex: Female, Male
Sex: Female, Male(Participants)Infanrix Hexa GroupPediarix GroupPentacel GroupTotal
Female1018095276
Male94114101309
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Infanrix Hexa GroupPediarix GroupPentacel GroupTotal
Asian - Japanese Heritage1012
African Heritage / African American1692045
Asian - East Asian Heritage3205
White - Caucasian / European Heritage118128115361
Asian - Central/South Asian Heritage2215
White - Arabic / North African Heritage0101
Unspecified29273288
American Indian or Alaskan Native15151747
Native Hawaiian or Other Pacific Islander2125
Asian - South East Asian Heritage99826
08

Study locations

43 sites
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Fayetteville, Arkansas 72703, United States
  • GSK Investigational Site
    Anaheim, California 92804, United States
  • GSK Investigational Site
    Daly City, California 94015, United States
  • GSK Investigational Site
    Fresno, California 93726, United States
  • GSK Investigational Site
    Hayward, California 94545, United States
  • GSK Investigational Site
    Oakland, California 94611, United States
  • GSK Investigational Site
    Pleasanton, California 94588, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    Sacramento, California 95815, United States
  • GSK Investigational Site
    Sacramento, California 95823, United States
  • GSK Investigational Site
    San Jose, California 95119, United States
  • GSK Investigational Site
    Santa Clara, California 95051, United States
  • GSK Investigational Site
    Walnut Creek, California 94596, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80922, United States
  • GSK Investigational Site
    Altamonte Springs, Florida 32701, United States
  • GSK Investigational Site
    Orange City, Florida 32763, United States
  • GSK Investigational Site
    Marietta, Georgia 30062, United States
  • GSK Investigational Site
    Woodstock, Georgia 30189, United States
  • GSK Investigational Site
    Nampa, Idaho 83686, United States
  • GSK Investigational Site
    Augusta, Kansas 67010, United States
  • GSK Investigational Site
    Newton, Kansas 67114, United States
  • GSK Investigational Site
    Topeka, Kansas 66604, United States
  • GSK Investigational Site
    Wichita, Kansas 67205, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Louisville, Kentucky 40291, United States
  • GSK Investigational Site
    Nicholasville, Kentucky 40356, United States
  • GSK Investigational Site
    Columbia, Maryland 21045, United States
  • GSK Investigational Site
    Kansas City, Missouri 64108, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Dayton, Ohio 45414, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16505, United States
  • GSK Investigational Site
    Sellersville, Pennsylvania 18960, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Payson, Utah 84651, United States
  • GSK Investigational Site
    Provo, Utah 84604, United States
  • GSK Investigational Site
    Saint George, Utah 84790, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    South Jordan, Utah 84095, United States
  • GSK Investigational Site
    West Jordan, Utah 84088, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22902, United States
  • GSK Investigational Site
    Ellensburg, Washington 98926, United States
09

References and documents

Publications

  • Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Hum Vaccin Immunother. 2019;15(4):809-821. doi: 10.1080/21645515.2018.1549449. Epub 2019 Jan 4. PubMed 30444673 ↗

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Feb 2015, 9 months.

Results were first posted in Aug 2018, 3 years 5 months after primary completion. A results delay was requested in Aug 2017.

Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 9 months is below that.

Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2014
First posted
Mar 26, 2014
StartActual
Apr 16, 2014
Primary completionActual
Feb 6, 2015
CompletionActual
Nov 13, 2015
Results delay requested
Aug 30, 2017
Results first posted
Aug 1, 2018
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02096263
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 26, 2014
Start date
Apr 16, 2014
Primary completion
Feb 6, 2015
Completion
Nov 13, 2015
Results posted
Aug 1, 2018
Last update
Nov 27, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion